Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published Date June 2007 Volume 2007:3(2) Pages 237—243

DOI http://dx.doi.org/

Published 8 June 2007

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects

Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG

Neuropsychiatric Disease and Treatment 2012, 8:347-353

Published Date: 1 August 2012

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Impact of lifestyle and technology developments on sleep

Shochat T

Nature and Science of Sleep 2012, 4:19-31

Published Date: 6 March 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Increased leptin/leptin receptor pathway affects systemic and airway inflammation in COPD former smokers

Bruno A, Alessi M, Soresi S, Bonanno A, Riccobono L, Montalbano AM, Albano GD, Gjomarkaj M, Profita M

Journal of Inflammation Research 2011, 4:51-59

Published Date: 20 May 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor

Yukio Sassa, Yasuaki Hata

Clinical Ophthalmology 2010, 4:275-283

Published Date: 1 April 2010